Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Go here for a timeline of WAVX:
http://timelines.ws/subjects/WaveSystems.HTML
CH stepped into a ramshackle operation and promptly began cleaning house. She found the foundation lacking and began structural fixes. She found numerous problems and began addressing them all getting rid of operations that showed no clear potential and focused on new operations that would feed the bottom line as well as the financing to make it happen.
If there was any time to invest in Hartcourt, now is it.
It would be nice to know the total holdings of the WAVX oficers. Perhaps they all own a lot already and its significant that they have not sold.
Pres. Bush in his State of the Union address has called for the use of DNA evidence in all capital offense cases.
Dell Inc. Installs
Security Chip
In Business PCs
By GARY MCWILLIAMS
Staff Reporter of THE WALL STREET JOURNAL
February 2, 2005; Page D4
Dell Inc. said it is supporting an industry effort to beef up corporate personal-computer security, by installing a dedicated chip that adds security and privacy-specific features to its computers.
Dell released three new Latitude PCs that are the first to add the security hardware, known as the Trusted Computing Module, and said the features would be included in future business PCs. TCM allows a computer to verify its identity and software capabilities in order to gain access to a network, in much the same way a password identifies an employee logging on to a corporate network.
Alex Gruzen, a Dell senior vice president, said that by adding the security hardware to its business machines, the company expects operating-system suppliers to develop future releases that assume the use of the hardware. Dell is currently using third-party software with the feature.
The company announced four new portable PCs and a new desktop PC in New York, to highlight what Mr. Gruzen said was the Round Rock, Texas, company's commitment to the PC market.
"At a time when many of our competitors are going through reorganizations, Dell continues to invest, continues to innovate and continues to grow [in the PC business]. This is a strong and growing business for us," he said.
The TCM hardware will be included with Dell's new Latitude D410, D610 and D810 computers, which are priced from about $1,400 and up. The company also introduced a new mobile engineering workstation, the Precision M20, which starts at $1,649.
Dell's support for the security push comes in the wake of similar endorsements by PC industry giants Advanced Micro Devices Inc., Hewlett-Packard Co., Intel Corp. and International Business Machines Corp.
The technology has been promoted by an industry organization called the Trusted Computing Group.
By CHRISTOPHER WINDHAM
Staff Reporter of THE WALL STREET JOURNAL
February 1, 2005; Page B4
In the latest study to wade into the question of whether race is a biologically based category or a socially constructed label, scientists at Stanford University claim to have found that 326 genetic 'markers' -- segments of DNA -- can be used to cluster people into four groups, with each group corresponding to common racial categories: white, African-American, East Asian and Hispanic.
For more than a decade some geneticists and anthropologists have argued that race isn't biologically real and therefore shouldn't be used in medical research and clinical practice. The argument is based on the fact that, for thousands of years, humans have been marrying and having children with people of different ancestry, with the result that everyone's genes come from the same big, humanwide pool. The mapping of the human genome and growing interest in race-based pharmaceuticals have stirred the debate in recent years.
The study, published in the February issue of the American Journal of Human Genetics, involved 3,636 people enrolled in a large trial on the genetics of hypertension. To see whether genetic markers correspond to the standard racial categories, the scientists first analyzed the volunteers' DNA, identifying which genetic markers they carried. They then used a computer program to cluster people based on genetic similarities; those who shared genetic markers were grouped together. Finally, the scientists compared those groupings with the volunteers' self-identified race. The result: people who considered themselves white had been grouped by the computer, based on their genetic markers, in one cluster, while people who consider themselves African-American had been grouped in a second, different cluster. The same held for Hispanics and East Asians. Only five people had DNA that matched an ethnic group different than the racial or ethnic box they checked at the outset of the study.
"People have argued that race and ethnicity are purely social categories," says Neil Risch, the study's lead author, who is director of the Center for Human Genetics at the University of California, San Francisco. "We've shown that socially defined ethnic categories correspond with genetic categories." The findings are convincing because of the large number of genetic markers -- 326 -- used to cluster the participants, he says.
The study of the relationship between race and genetics largely is viewed in the medical community as a way to better understand why some ethnic groups suffer and die disproportionately from certain illnesses than others. It also could help physicians predict which patients might respond better to certain drugs, geneticists say.
But using random genetic markers to show links to ancient geographic ancestry doesn't reveal much about how such markers might be predictive in disease, says geneticist J. Craig Venter, who led the private effort to sequence the human genome and is part of the J. Craig Venter Institute. The markers aren't actually genes, but merely segments of DNA whose function is unknown.
Re InterTrust Tech: Company profile
Trust InterTrust Technologies' technology to protect your digital content. The company's digital rights management and trusted computing technology helps protect and manage content rights for companies that distribute music, movies, information, and other digital content. Intertrust's software covers Internet, wireless, and cable distribution, as well as content burned on disks. InterTrust's technology delivers authorization access in RightsPacks, digital packages that allow users to access files according to the level of access specified. In 2003, the company was acquired for $453 million by Fidelio Acquisition Company, a firm whose investors include Royal Philips Electronics and Sony Corporation of America.
http://www.intertrust.com/main/overview/
Re:
Intertrust Technologies, a small United States-based company which owns many of the crucial patents for digital anti-piracy protection, is also part of the alliance.
2000 Dec 19, Wave Systems Corp. and InterTrust Technologies Corporation (ITRU) announced today that they are collaborating to create the industries' premier high-end digital rights management solution, using Wave's EMBASSY® Trusted Client programmable hardware system, as the newest platform in the recently announced InterTrust RightsChip family.
(IHub, #25184, 1/6/04)
Good summary by Walsh. I was also pleased to hear that Carrie was happy with her job. She acknowledged problems and seems to have put the major ones to rest. The groundwork is laid and I see bright prospects moving forward.
NEW YORK (CBS.MW) -- Shares of Alvarion Ltd. (ALVR) were taking an 11-percent dive after Merriman Curhan Ford downgraded the company to "neutral" from "buy" due to concerns over the timing of revenue generation. Analyst Kevin Dede said he has yet to see evidence that broadband wireless deployments in China will increase to a meaningful level and the he is still skeptical that the company's key customer in Latin America will continue to increase its fixed wireless deployments at the current pace. He is also unsure whether new business from the InterWave acquisition can offset less business in other sectors. Dede cut his 2005 earnings estimate to 20 cents a share from 42 cents and his revenue forecast to $250 million from $286 million. The stock was shedding $1.39 to a 4 1/2-month low of $11.
Here are the remarks:
Company: Wave Systems Ticker: WAVX
Sub-sector: Security
Investment Thesis: I first encountered Wave when I wrote my initial analyst report on Wall Street in the mid-1990s. Wave has remained in business largely by claiming that it is developing revolutionary security technologies, kind of like a bio-tech company that never gets out of trials. With a grand total of $1.4M in revenues over the last 3.5 years, almost $14M in cash burn during the first nine months of this year and only $6M in cash left, Wave finally appears to be approaching judgment day. It may take a few more quarters, but I fully expect Wave to follow in the footsteps of CMRC or to wash out the existing common with a new financing.
Performance: Since 10/1/04: -25.7% Nov vs Dec: -41.2%
Comments: I guess this stock proves the lesson that you should never underestimate what desparate men will do. Running low on cash in early December, Wave made an announcement on 12/14 that they had released a version of their software for a potential Dell OEM deal. The stock promptly jumped 80% on 20M shares in volume. Never mind that Dell has not committed to selling the software, that the software retails for only $20/copy and that the Dell OEM version was basically just a rebranding of an existing version that a distributor called Embassy was already selling on Wave's behalf. Then on the 16th, Wave drops another press release saying that the company has won a contract with the US Army. That generates about 8M shares of volume at $1.36/share. Lo and behold on the 17th, Wave announces that it has closed a $5.8M private placement, just in the nick of time, but unlike the other private placements it has done (in which it sold the stock at market close and offered out of the money warrants) this placement sold the stock at $1.05/share or a whopping 23% discount to the close of the stock on the day the deal was agreed. Any trader worth his salt knows how this deal went down. Wave's placement agent had the deal teed up and ready to go, probably for several weeks. The agent undoutedly knew that there would be some good news coming that would help the stock trade up dramatically. Once that news was announced, the investors went into the market and in the midst of the greatly increased positive volume were able to sell short almost their entire position. With their position locked in, the investors signed the deal and promptly covered their short with the delivered shares. Wallah! A 23% guaranteed, overnight profit. God bless America! This is one of the oldest penny stock tricks in the book, it's just surprising to see it used so blantently in this day and age of Sarbanes-Oxley, etc. Just to make this situation even more comical, on the 20th, which was likely well after all the shorts were covered, Wave quitely filed an 8K with the SEC in which they mentioned that the US Army contract was for a whopping $80K, a fact they ommitted from the press release on the 16th. And why not, $80K is not going to make much of a dent in a $4.5M/quarter burn rate. The only solace I take from this episode is that it smacks of true desperation to me. By playing these kind of penny stock games, Wave is clearly indicating that it can no longer get reputable investors to buy from its "shelf offering". At their current burn rate they will have to go back to the shelf by the end of this quarter or early next quarter so it will be interesting to see just how much juice they will have to offer to get the deal done. It will also be interesting to see just how much they are willing to risk attracting SEC attention with another one of their pump, short, issue, cover schemes. While they may be able to keep up the charade for another quarter or so, I like the smell of desperation and therefore I am keeping my short on.
I have benn following ALVR for quite some time.
Alvarion new name Breezecom and Floware 8/1/2001
Alvarion net loss [.72] vs .08, rev 22 mil 8/3/2001
Alvarion net loss [.08] vs [.10], rev 22.4 mil vs 22.3 5/22/2003
Alvarion net loss [.11] vs [.08], rev 31 mil 7/30/2003
Alvarion net loss [.04] vs [.09], rev 34 mil 11/8/2003
Alvarion none 0 vs [.10], rev 39.5 mil 2/10/2004
Alvarion net up .02 vs [.08], rev 44 mil 5/6/2004
Alvarion net up .04 vs [.11], rev 48 mil 8/6/2004
Alvarion net up .06 vs [.04], rev 52 mil 11/4/2004
Maybe by the Olympics, maybe later. Certainly before year 3000.
Here is a link to the updated Wave Systems Timeline:
http://timelines.ws/subjects/WaveSystems.HTML
Yes indeed, a little baby, beautiful Oriental Shepherd with huge paws.
FDA Clears Test of Patient DNA
To Screen for Drug Effectiveness
Associated Press
December 24, 2004; Page A9
WASHINGTON -- The Food and Drug Administration said it approved a test that will allow doctors to check a patient's DNA when choosing certain medications.
The FDA called it the first laboratory test system for doctors to use in reviewing patients' genetic information. It is meant to improve doctors' ability to prescribe medications for conditions such as cancer and heart and psychiatric diseases. The agency said the specific enzyme analyzed by this test plays a key role in the body's ability to metabolize some commonly prescribed drugs including antidepressants, antipsychotics, beta-blockers and some chemotherapy drugs.
The new test is the first DNA microarray test to be cleared by the FDA and paves the way for similar microarray-based diagnostic tests to be developed.
"Physicians can use the genetic information from this test to prevent harmful drug interactions and to assure drugs are used optimally, which in some cases will enable patients to avoid less effective or potentially harmful treatment choices," said acting FDA commissioner Lester M. Crawford.
The new test is the AmpliChip Cytochrome P450 Genotyping Test made by Roche Molecular Systems Inc., Pleasanton, Calif. The FDA said the test was cleared for use with the Affymetrix GeneChip Microarray Instrumentation System, manufactured by Affymetrix Inc., Santa Clara, Calif.
The test uses DNA from a patient's blood. It analyzes one of the genes from a group called cytochrome P450 genes, which are active in the liver to break down certain drugs and other compounds.
Variations in this gene can cause a patient to metabolize certain drugs more quickly or more slowly than average, or, in some cases, not at all, the FDA said.
WSJ 12/24/04
FDA on DNA:
FDA Clears Test of Patient DNA
To Screen for Drug Effectiveness
Associated Press
December 24, 2004; Page A9
WASHINGTON -- The Food and Drug Administration said it approved a test that will allow doctors to check a patient's DNA when choosing certain medications.
The FDA called it the first laboratory test system for doctors to use in reviewing patients' genetic information. It is meant to improve doctors' ability to prescribe medications for conditions such as cancer and heart and psychiatric diseases. The agency said the specific enzyme analyzed by this test plays a key role in the body's ability to metabolize some commonly prescribed drugs including antidepressants, antipsychotics, beta-blockers and some chemotherapy drugs.
The new test is the first DNA microarray test to be cleared by the FDA and paves the way for similar microarray-based diagnostic tests to be developed.
"Physicians can use the genetic information from this test to prevent harmful drug interactions and to assure drugs are used optimally, which in some cases will enable patients to avoid less effective or potentially harmful treatment choices," said acting FDA commissioner Lester M. Crawford.
The new test is the AmpliChip Cytochrome P450 Genotyping Test made by Roche Molecular Systems Inc., Pleasanton, Calif. The FDA said the test was cleared for use with the Affymetrix GeneChip Microarray Instrumentation System, manufactured by Affymetrix Inc., Santa Clara, Calif.
The test uses DNA from a patient's blood. It analyzes one of the genes from a group called cytochrome P450 genes, which are active in the liver to break down certain drugs and other compounds.
Variations in this gene can cause a patient to metabolize certain drugs more quickly or more slowly than average, or, in some cases, not at all, the FDA said.
wsj 12/24/04 p.9
End of year tax selling plus new accumulation.
Thanks AWK
Indeed awesome!
No! First we need to get to .19
If you're happty with just one vette, go ahead and sell.
The buying was strong right into the close. It should continue in the am. This info has not yet hit the public in the face.
Fuzzy money. Gloat on.
Your dollar payments are still in your earned dollars. The drop in the value of the dollar comes back to kick you in the but when you try to buy another real asset, e.g. a proportianally inflated home with accompanying higher property taxes. The government gets to pay its fixed debts back with cheaper dollars. You Mssr. taxpayer get to pay higher property taxes with your fixed, and cheaper dollars.
Here I am. DNAP will save the world. This is a great PPS to get in. Tax loss selling is knocking the SP way down. Time to load up for the long haul. I just scored another 100 shares. LOL
A linear projection would make it around 322k.
OT:
I've driven American cars for 35 years.
But I just purchased a Honda Element. It was the only vehicle I could find that allowed me to put my bicycle inside standing up. The rear seats fold up against the side walls creating a large amount of rear space. No US car has this.
It is often difficult to distinguish between fact and fiction. In a humble effort to continue this venerable tradition I would like to submit the following: The regular "Hair Today" column will not appear as my star reporter StarLa is out on assignment studying the grooming practices of American house cats. In lieu of *La’s featured piece I would like to bring you up to date on the back-office affairs here at www.timelines.ws.
Due to the diminishing value of the US dollar, the general uncertainties of the international economic picture and mounting local expenses, it has become necessary to re-organize and restructure all com-pany operations. I have laid off my employer, eliminated all corporate perks and destroyed all corporate credit cards. My human resources dept., plant engineering, and employee deli have all been closed down. I have also outsourced all my data collection operations to the Associated Press, the Wall Street Journal, the San Francisco Chronicle, American History magazine, The Economist, National Geographic, Archeology magazine and the Organization of American Historians (OAF). To ensure quality control I have decided to retain all copy-selection and editing privileges. I have also decided to out-source all marketing and sales operations to my offshore subsidiary www.timelines.ws/offshore. However, I have decided keep the communications operations fully intact and accessible 24/7/365.25 at aalgis@aol.com.
In order to obtain capital for further growth my financial officer has recommended that I consider tap-ping into the private equity markets. I am now rewriting the company business plan to accommodate this change in direction and expect to soon launch a request for $500,000 in equity capital as a Limited Liability Partnership (LLP). This amount represents the current approximate value of company operations. Shares in the new LLP will be available in increments of $1000. Should you be interested in a prospectus please contact me via the communications center listed above.
It is a bit lonely here, now that operations have been sheered to the bone, but in honest truth it’s been that way for ten years now. As I see it the current layoffs and cutbacks can always be reversed. The new restructure will allow me devote full time to company operations and long term growth. Needless to say I have provided an exceptional severance package for those I was forced to let go. I also had them all sign legal documentation with quit claims and guarantees not to disclose company secrets or harbor ill will.
Please bear with us through this difficult period.
Algis Ratnikas
Sole Proprietor www.timelines.ws LLP
ROTFL
Aint that the truth.
Mothers are so sly.
That's a mere 20k. Go ahead. Splurge. Buy more. It's only money.
You must be of the chameleon or octopus family.
Alas and alack for the rest of us dumb skinned beings.
The web site and annoucement will be ready for public releases after thanksgiving holiday. thanks and have a great holiday. david.
Perhaps its time for a treehouse.
Indeed for good and forever.
No. Just a general market downtrend.
I waited 2 days for a fill at 17 with no luck. Raised it to 18 yesterday and it filled 1st thing today...
You might also try 1-800-scramjet
Call Spiderman for help.
Which side of the limb are you sawing from?
I would like to e-mail Carrie Hartwick with a specific question on PC motherboard sales via Hartcourt outlets.
There is new security technology rapidly becoming available that is based on a chip called a Trusted Computing Module (TPM).
Since part of Harcourt's holdings specialize in custom built PCs, the question is whether Hartcourt's outlets have noticed an uptick in requests for motherboards that feature a TPM.
You can go to this site to see a matrix of the TPM rollout.
http://www.tonymcfadden.net/tpmvendors.htm#motherboard
Please let me know Carrie's e-mail address.
74 is 9 times better than 666 and hopefully much more reflective of HRCT's future direction.